P., Stolte, E
Aqua, Glycerin, Diisostearyl Malate, Tridecyl Trimellitate, Pentaerythrityl Tetraisostearate, Hydrogenated Polyisobutene, Isododecane, Hydroxystearic Acid, Titanium Dioxide, Aluminum Hydroxide, Triethoxycaprylylsilane, Ozokerite, Daemonorops Draco (Dragon Blood) Extract, Perfluorooctyl Triethoxysilane, Cervus Elaphus (Placental) Extract, Cordyceps Sinensis Extract, Tocopherol (Vitamin E), Phenoxyethanol, Sodium Polyacrylate, Ascorbic Acid (Vitamin C), Methylparaben, Panax Ginseng Root Extract, Butylene Glycol, Sodium Hyaluronate, Fragrance, CI 19140, Niacinamide, Glutathione, Placental Protein
SLU-PP-332's pharmacological positioning is that of a **synthetic agonist of all three paralogs ERRalpha, beta, gamma** (Estrogen-Related Receptors), orphan nuclear receptors discovered by Vincent Giguere in 1988
Unlike CJC-1295 with DAC, the no-DAC variant does not include the Drug Affinity Complex for albumin binding, resulting in a shorter half-life of approximately 30 minutes and a more physiologically pulsatile GH release profile in research models